atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment Post published:November 17, 2022 Post category:Press Release
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update Post published:November 10, 2022 Post category:Press Release
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences Post published:November 2, 2022 Post category:Press Release
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression Post published:October 25, 2022 Post category:Press Release
atai Life Sciences Announces R&D Day Agenda Post published:October 21, 2022 Post category:Press Release
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology Post published:October 19, 2022 Post category:Press Release
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD Post published:October 13, 2022 Post category:Press Release
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT Post published:October 5, 2022 Post category:Press Release
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01 Post published:September 27, 2022 Post category:Press Release
atai Life Sciences to Participate in September Investor Events Post published:September 8, 2022 Post category:Press Release